Overview

Transition From Acute to Chronic Back Pain : Effect of L-dopa,Gender,and Associated Brain Plasticity

Status:
Withdrawn
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a 6-month double-blinded, randomized, placebo-controlled clinical trial of pharmacological treatment (carbidopa/levodopa and celecoxib) for acute/subacute back pain. All eligible patients will be randomly assigned to 3 different group and receive a 12-week treatment of "carbidopa/levodopa+celecoxib ", of "placebo+celecoxib", and of "placebo+placebo". In addition, all participants will be MRI-scanned twice and assessed daily with a mobile app for pan, mood, and behavior.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital of Wenzhou Medical University
Collaborator:
Northwestern University
Treatments:
Carbidopa
Carbidopa, levodopa drug combination
Celecoxib
Levodopa